NVCR

12.62

1.02% -0.13

Dopo l'orario di chiusura: 12.62

Novocure Ltd (NVCR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NVCR Giù? Forum Previsione

Precedente Chiudi:

$12.75

Aprire:

$12.57

Volume 24 ore:

972.83K

Relative Volume:

0.53

Capitalizzazione di mercato:

$1.44B

Reddito:

$655.35M

Utile/perdita netta:

$-136.23M

Rapporto P/E:

-10.32

EPS:

-1.2223

Flusso di cassa netto:

$-75.68M

1 W Prestazione:

-5.96%

1M Prestazione:

+20.19%

6M Prestazione:

-0.86%

1 anno Prestazione:

-40.81%

Intervallo 1D:

$12.23

$12.74

Intervallo di 1 settimana:

$12.23

$14.33

Portata 52W:

$9.82

$21.55

Novocure Ltd Stock (NVCR) Company Profile

Nome

Novocure Ltd

Settore

Healthcare (1109)

Industria

Medical Devices (143)

Telefono

44 (0)15 3475 6700

Indirizzo

NO. 4 THE FORUM, ST. HELIER

Dipendente

1,605

Cinguettio

@novocure

Prossima data di guadagno

2026-04-23

Ultimi documenti SEC

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVCR Novocure Ltd	12.62	1.45B	655.35M	-136.23M	-75.68M	-1.2223
ABT Abbott Laboratories	110.25	192.10B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	345.78	137.25B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	88.97	115.41B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	69.63	103.81B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	85.09	49.82B	6.07B	1.06B	1.34B	1.8063

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-07-08	Iniziato	Ladenburg Thalmann	Buy
2024-12-02	Aggiornamento	Evercore ISI	In-line → Outperform
2024-10-16	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-28	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-08	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-04	Iniziato	SVB Securities	Outperform
2023-07-31	Aggiornamento	Evercore ISI	Underperform → In-line
2023-06-07	Aggiornamento	Wedbush	Underperform → Neutral
2023-05-16	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2023-01-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-01-05	Reiterato	H.C. Wainwright	Buy
2022-11-29	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-24	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-05	Downgrade	Evercore ISI	In-line → Underperform
2022-05-16	Iniziato	H.C. Wainwright	Buy
2022-02-08	Iniziato	Loop Capital	Buy
2022-02-02	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-20	Aggiornamento	Truist	Hold → Buy
2022-01-03	Aggiornamento	Evercore ISI	Underperform → In-line
2021-07-01	Downgrade	Mizuho	Buy → Neutral
2021-04-14	Downgrade	Wedbush	Neutral → Underperform
2021-01-25	Reiterato	Piper Sandler	Overweight
2020-09-23	Iniziato	Northland Capital	Outperform
2020-09-18	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-17	Downgrade	Truist	Buy → Hold
2020-06-01	Ripresa	Oppenheimer	Perform
2020-05-01	Downgrade	Oppenheimer	Outperform → Perform
2020-04-09	Downgrade	Evercore ISI	In-line → Underperform
2020-03-05	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-07-29	Aggiornamento	SunTrust	Hold → Buy
2019-07-26	Downgrade	JP Morgan	Overweight → Neutral
2019-07-26	Downgrade	Wedbush	Outperform → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2018-11-02	Downgrade	Wells Fargo	Outperform → Market Perform
2018-07-16	Iniziato	Evercore ISI	Outperform
2018-04-18	Reiterato	Mizuho	Buy
2018-02-23	Reiterato	Mizuho	Buy
2017-05-24	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-07-29	Reiterato	Wedbush	Outperform
2016-01-19	Iniziato	Barclays	Underweight
2015-12-02	Iniziato	Deutsche Bank	Hold

Mostra tutto

Novocure Ltd Borsa (NVCR) Ultime notizie

06:04 AM

FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News

06:04 AM

Mar 10, 2026

Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com India

Mar 10, 2026

Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia

Mar 10, 2026

Mar 09, 2026

Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - simplywall.st

Mar 09, 2026

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance

Mar 09, 2026

Mar 06, 2026

Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm

Mar 06, 2026

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 06, 2026

Mar 05, 2026

NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat

Mar 05, 2026

NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat

Mar 05, 2026

Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat

Mar 05, 2026

Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan

Mar 03, 2026

NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan

Mar 03, 2026

Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan

Mar 03, 2026

NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan

Mar 03, 2026

NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm

Mar 03, 2026

Mar 02, 2026

Novocure gains Japan reimbursement for Optune Lua device - Investing.com Australia

Mar 02, 2026

NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha

Mar 02, 2026

NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union

Mar 02, 2026

NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance

Mar 02, 2026

Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus

Mar 02, 2026

Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus

Mar 02, 2026

Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com Canada

Mar 02, 2026

Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan

Mar 02, 2026

Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat

Mar 02, 2026

A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance

Mar 02, 2026

Mar 01, 2026

NovoCure Earnings Call: Growth Builds Amid Profit Strain - TipRanks

Mar 01, 2026

NovoCure Ltd. Opens with 6.47% Gain, Outpacing S&P 500's 0.69% Rise - Markets Mojo

Mar 01, 2026

NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo

Mar 01, 2026

NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo

Mar 01, 2026

NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo

Mar 01, 2026

Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st

Mar 01, 2026

Feb 28, 2026

NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st

Feb 28, 2026

Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat

Feb 28, 2026

Feb 27, 2026

Novocure CEO and CFO to field investor questions at Leerink event - Stock Titan

Feb 27, 2026

NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 27, 2026

Novocure to Participate in 2026 Leerink Global Healthcare Conference - Yahoo Finance

Feb 27, 2026

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Feb 27, 2026

Feb 26, 2026

NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat

Feb 26, 2026

NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st

Feb 26, 2026

NovoCure: Q4 Earnings Snapshot - theheraldreview.com

Feb 26, 2026

NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Feb 26, 2026